Related Experiment Videos
The disposition of indomethacin in preterm babies
Insights
This study on indomethacin in preterm infants found that intravenous administration leads to variable drug levels. Female infants and younger infants had lower concentrations, suggesting altered drug disposition in premature neonates.
Area of Science:
- Neonatal Pharmacology
- Pediatric Clinical Pharmacology
- Drug Metabolism and Disposition
Background:
- Limited pharmacokinetic data exists for indomethacin in preterm infants.
- Poor or incomplete oral absorption necessitates alternative administration routes.
- Hemodynamically significant patent ductus arteriosus is a common condition in preterm neonates requiring treatment.
Purpose of the Study:
- To provide pharmacokinetic data on intravenous indomethacin in preterm infants.
- To investigate factors influencing indomethacin disposition, including sex and extrauterine age.
- To inform dosing strategies for indomethacin in this vulnerable population.
Main Methods:
- Pharmacokinetic analysis of 37 preterm infants receiving intravenous indomethacin.
- Measurement of serum indomethacin concentrations at various time points post-dose.
- Correlation of drug levels with infant sex and postmenstrual age.
Main Results:
- Variable serum indomethacin concentrations observed between 4 and 12 hours post-dose.
- Female infants generally exhibited lower serum indomethacin levels compared to males at later time points.
- Significant correlation found between extrauterine age and serum indomethacin levels, total body clearance, serum half-lives, and volume of distribution.
Conclusions:
- Intravenous indomethacin administration in preterm infants results in variable drug exposure.
- Extrauterine age is a critical determinant of indomethacin pharmacokinetics, influencing its duration of action and potential for accumulation.
- Dosing adjustments may be necessary based on infant sex and post-birth age to optimize therapeutic efficacy and minimize toxicity.
Abstract:
Limited pharmacokinetic data are available concerning the disposition of indomethacin in preterm infants. Since oral absorption of the drug may be poor or incomplete, the current report provides pharmacokinetic data on 37 premature infants who received indomethacin intravenously. Each of these infants had a hemodynamically significant patent ductus arteriosus. Findings included variable serum indomethacin concentrations from four to 12 hours after a single dose of 0.2 mg/kg. Female preterm infants generally had lower serum drug values at 12 hours and beyond when compared to males. An extrauterine age dependence was found of serum indomethacin levels. Total body clearance, serum half lives and volumes of distribution also bore a direct relationship to extrauterine age. Thus, when indomethacin is administered shortly after birth, one may anticipate a longer duration of action after a single dose and a relatively greater risk of accumulation of the drug when more than one dose is required for treating a duct al patency.